George-Huntington-Institut GmbH
- Address
- lock Available on a paid plan
Diseases of the Nervous System
The George-Huntington-Institut GmbH is contributing to clinical research focused on Huntington’s disease, a serious nervous system disorder that affects movement, thinking, and behavior. The trials in this area are designed to assess whether new approaches can help manage the disease more effectively while also monitoring overall safety and patient response.
- Testing new therapies for Huntington’s disease
- Evaluating treatment safety and tolerability
- Measuring effects on disease-related biological markers
This research helps expand understanding of how emerging treatments may influence disease activity and support better care for people living with this inherited condition.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
At this research site in Münster, Germany, clinical studies also address hereditary disease research, with a strong emphasis on Huntington’s disease as an inherited condition passed through families. The trials are aimed at improving the understanding of genetic disease progression and at exploring whether novel treatments can alter key disease-related signals in the body.
- Studying inherited forms of Huntington’s disease
- Assessing whether treatments can reduce harmful protein levels
- Supporting development of more effective disease-targeted care
The work reflects a broader interest in genetic and hereditary disorders, with research centered on therapies that may slow progression or improve measurable disease outcomes.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
- 1Novartis Pharma AG1active
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novartis Pharma AG2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in George-Huntington-Institut GmbH
lock Showing 1 of 5 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of ALN-HTT02 in Adult Patients with Huntington's Disease | Alnylam Pharmaceuticals Inc. | Phase I | Recruiting | Mar 2025 | — |
IMP list
lock Showing 1 of 2 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| VOTOPLAM | 2 | Unknown | 2023-10-31 | 2026-07-28 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.